Showing 1–25 of 26 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Claudio Damião Rosa, Lucilaine Ferrazoli, Debora Pereira Dos Santos, Carolina Pedace, Naila Cristina Soler-Camargo, et al.
… whole-genome sequencing (WGS) ofcomplex isolates to detect drug-resistant tuberculosis (DR-TB). This endorsement was based on the assumption that a faster and more detailed description of the resistance profile would improve treatment prescription for DR-TB by healthcare provide…
Bella Devaleenal Daniel, Sivakumar Shanmugam, Rashi Mehta, Manpreet Bhalla, Muthuvijayalakshmi Mariappan, et al.
…on of linezolid at the end of 48 weeks post treatment among drug resistant tuberculosis (DR TB) patients. **METHODS:** Multicentric pragmatic randomized clinical trial in which BPaL regimens were given for 26 weeks for pulmonary pre extensively drug resistant tuberculosis (PreXD…
Pawandeep Kaur, Lelia H Chaisson, Zana Wangari Kiragu, Praewpannarai Buddadhumaruk, Ariana F Austin, et al.
…*BACKGROUND:** Current guidelines for the treatment of multidrug-resistant/rifampin-resistant tuberculosis (MDR/RR-TB) are based on clinical trials evaluating fixed duration regimens. However, when a regimen succeeds, it remains unknown whether a shorter duration could yield the …
Mailing Huang, Yujin Wang, Tao Chen, Yu Lu, Naihui Chu, et al.
… 0.008). Blood concentrations were higher than CSF for both drugs at all time points. No serious drug-related adverse events occurred. Contezolid effectively penetrates the blood-CSF barrier in TBM patients, achieving CSF concentrations above the MIC for Mtb. Although its CSF exp…
Lorenzo Guglielmetti, Uzma Khan, Gustavo E Velásquez, Maelenn Gouillou, Muhammad Hammad Ali, et al.
**BACKGROUND:** Pre-extensively drug-resistant (pre-XDR) tuberculosis (ie, multidrug-resistant or rifampicin-resistant with additional resistance to any fluoroquinolone) is difficult to treat. endTB-Q aimed to evaluate the efficacy and safety of bedaquiline, delamanid, linezolid,…
J Shenje, G Maartens, L Moran, Y Cramer, J D L Rios, et al.
…><title>BACKGROUND</title>Bedaquiline and delamanid are key drugs in the treatment of multidrug-resistant TB. It is unclear whether HIV affects the pharmacokinetics of bedaquiline and delamanid.</sec><sec><title>METHODS</title>Participants with multidrug-resistant TB were randomi…
Laura Iavarone, Silvia M Lavezzi, Antonio J Carcas, Tetyana Chaychenko, Raquel Gabarro-Carrion, et al.
New drugs are urgently needed to treat drug-resistant tuberculosis in combination regimens. Ganfeborole demonstrated bactericidal activity and good tolerability in clinical trials. In preclinical studies, ganfeborole showed embryofetal developmental effects, currently mandating h…
Linda J Harrison, Gustavo E Velásquez, Russell R Kempker, Marjorie Z Imperial, Eric Nuermberger, et al.
**BACKGROUND:** The standard of care (SOC) treatment for drug-susceptible pulmonary tuberculosis (DS-TB) consists of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). New treatment regimen options for DS-TB are needed as HRZE is long in duration (6 months), associa…
Yilin Zhang, Yang Li, Yan Ren, Ting Li, Yajiao Xing, et al.
…fficacy and safety of short-term regimens utilizing various drug combinations is essential across different settings. **METHODS:** INSPIRE TB is a pragmatic, multicentre, randomised, controlled, non-inferiority open-label trial to evaluate novel regimens in pulmonary RR-TB patie…
Weijie Kong, Hao Liang, Yi Zhang, Lei Li, Yongguo Li, et al.
…h bedaquiline (BDQ) received conditional approval for multi-drug resistance tuberculosis (MDR-TB), a black box warning was added due to QT prolongation risk. WX-081, a promising second-in-class drug that finished phase II clinical trial, exhibited comparable anti-TB activity and …
Feng Sun, Yang Li, Yilin Zhang, Cui Cai, Yuanyuan Chen, et al.
…TIVES:** Despite advancements in shorter, oral regimens for drug-resistant tuberculosis, more options are needed to extent patient benefits. We conducted a trial to evaluate the noninferiority of an all-oral regimen compared with the injectable-containing regimen. **METHODS:** I…
Nestani Tukvadze, Sehlomola Mashatole, Anne Jacobs, Tlhago Ngwanto, Norbert Heinrich, et al.
… inadequate, requiring participants closely adhere to multi-drug regimens that are long, complex, and often poorly tolerated. In addition to these well-recognized shortcomings, current TB treatments, particularly those for rifampicin-resistant tuberculosis, leave a majority of cu…
M Olugbosi, M Beumont, L Lombard, J Nedelman, J Timm, et al.
…rom a single infectious agent. Current standard of care for drug-sensitive tuberculosis (DS-TB) treatment has a long duration with risk of poor compliance and outcomes and increased risk of development of resistant strains. Sorfequiline (S) is a second-generation diarylquinoline …
Emilyn Costa Conceição, Karla Valéria Batista Lima, Cristiane Cunha Frota, Theolis Costa Barbosa Bessa, Adriana Ayden Ferreira, et al.
…WGS), which are pivotal for precision health approaches and drug-resistant TB (DR-TB) surveillance. This study aims to strengthen genomic TB surveillance in the North and Northeast Brazilian regions by applying WGS to study DR-TB cases, training professionals in genomics and bioi…
Lilian Tina Minja, Isabella van der Feltz, Christina Manyama, Stellah Mpagama, Francis Mhimbira, et al.
…nezolid plays a crucial role in the first-line treatment of drug-resistant tuberculosis globally. Its prolonged use can lead to neurological and haematological toxicity, highlighting the need for safer oxazolidinones. Delpazolid, a novel oxazolidinone, might be safer. We aimed to…
Norbert Heinrich, Christina Manyama, Simon E Koele, Stellah Mpagama, Francis Mhimbira, et al.
…zolid is a key component globally in first-line therapy for drug-resistant tuberculosis but has considerable toxicity. New and safer alternative oxazolidinones are needed. Sutezolid is one such promising alternative. We aimed to evaluate preliminary efficacy and safety of sutezol…
Yixuan Li, Yi Wu, Shufan Cai, Xiangxin Huang, Lijun Ye, et al.
**BACKGROUND AND OBJECTIVE:** Multidrug-resistant tuberculosis remains a major global health challenge, and bedaquiline has become an essential drug for its treatment. However, the high cost of the originator product Sirturolimits accessibility, underscoring the need for affordab…
Veronique de Jager, Laurynas Mockeliunas, Huifang You, Ulrika S H Simonsson, Tarryn Collings, et al.
**BACKGROUND:** In vitro, meropenem is shown to restore the activity of rifampicin in rifampicin-resistant Mycobacterium tuberculosis strains. This phase 2a trial aimed to determine if addition of rifampicin increases the early bactericidal activity (EBA) of meropenem plus amoxic…
Susan E Purchase, Joanna Brigden, James A Seddon, Neil A Martinson, Lee Fairlie, et al.
…ed <5 years exposed to adults with confirmed pulmonary multidrug-resistant (MDR)-TB and to determine risk factors for infection. **METHODS:** TB-CHAMP was a trial of MDR-TB prevention that recruited children younger than age 5 years, regardless of M. tuberculosis infection statu…
Patrick P J Phillips, Charles A Peloquin, Timothy R Sterling, Pawandeep Kaur, Andreas H Diacon, et al.
…sing has generally been inadequate during tuberculosis (TB) drug development. Fluoroquinolones are central to TB treatment.To determine the dose of levofloxacin needed to achieve maximal efficacy and acceptable safety and tolerability as part of a multidrug TB regimen.Opti-Q was …
Thanakorn Vongjarudech, Anne-Gaëlle Dosne, Bart Remmerie, Mats O Karlsson, Elin M Svensson
…valuating QT prolongation induced by anti-tuberculosis (TB) drugs in patients with active TB, who often experience tachycardia, is challenging due to the limitations of Fridericia's correction factor (QTcF) in decorrelating QTc from heart rate (HR). Previous exposure-QTcF analyse…
Jennifer A Hughes, Belén P Solans, Anthony J Garcia-Prats, Heather R Draper, H Simon Schaaf, et al.
…tics and safety of clofazimine in children treated for multidrug/rifampicin-resistant tuberculosis (MDR/RR-TB). **METHODS:** Children aged <18 years were eligible. Clofazimine was administered by weight-based dosing. Sparse and semi-intensive pharmacokinetic sampling was complet…
Saskia Janssen, Caryn Upton, Veronique R de Jager, Christo van Niekerk, Rodney Dawson, et al.
…eases.We randomly assigned 64 patients with smear-positive, drug-sensitive tuberculosis to daily telacebec 100, 200, or 300 mg, or standard four-drug treatment as control, for 14 days.Sputum collected overnight was cultured in liquid and on solid media to determine the change of …
Anushka Naidoo, Kogieleum Naidoo, Marothi P Letsoalo, Roeland E Wasmann, Gillian Dorse, et al.
…odified intention-to-treat population using the US Food and Drug Administration snapshot algorithm. All participants in the modified intention-to-treat population were included in the safety analyses (ie, all participants who received at least one dose of the study drug and had a…
Degu Jerene, Kristian van Kalmthout, Jens Levy, Jason Alacapa, Natasha Deyanova, et al.
… labels. We enrolled adult patients receiving treatment for drug-susceptible tuberculosis. The pillbox gave an audio-visual reminder to take medication, and when the box was opened, a signal was transmitted to the adherence platform. Those in the labels arm received medications w…